ArticleFrontiers in genetics2024
Awareness, use, motivations and methods of accessing genetic testing in 2022 in the United States.
Article in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.Clinical and translational science · 2026Trial
- Learning about a heightened genetic risk for dementia: Expected stigma is greater than experienced stigma.Psychology and aging · 2026Article
- The Australian Public's Awareness, Knowledge and Perspectives Towards Pharmacogenomics: A Nationwide Survey, and Semi-Structured Interviews.Clinical and translational science · 2026Article
- Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.Gynecologic oncology · 2026Article
- Multi-cancer early detection tests: national estimates of awareness and perceived value in the United States.Cancer causes & control : CCC · 2026Article
- Neighborhood Opportunity and Genetic Literacy in a Representative Sample of US Adults.Prevention science : the official journal of the Society for Prevention Research · 2026Article
- Misinterpreting the results: patient misconceptions about genetic cancer risk after obstetrical carrier screening.Familial cancer · 2026Article
- When genomics companies act as biobanks: governance challenges in an era of genomic assetization.Frontiers in genetics · 2026Article
- Prevalence of BRCA1 and BRCA2 Variants in an Unselected Population of Women With Breast Cancer.JAMA network open · 2025Article
- Prevalence of clinician-ordered genetic testing in rural and urban United States counties: An analysis of the 2022 Health Information National Trends Survey.Preventive medicine reports · 2025Article
- The Role of Online Support, Caregiving, and Gender in Preventative Cancer Genetic Testing Participation: Cross-Sectional Study From a National Study.JMIR cancer · 2025Article
- Neighborhood Disadvantage and Genetic Testing Use Among a Nationally Representative Sample of US Adults.Journal of primary care & community healthArticle
- Exploratory Analysis of Health Literacy and Genetic Testing Awareness, Uptake, and Desire for Genetic Risk Information: Findings From a Cross-Sectional Community Survey.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: Awareness, access, and use of clinical and direct-to-consumer (DTC) genetic tests has increased in recent years with documented disparities in these services. We provide updated data on test awareness and use, and report novel data on motivations and methods for accessing genetic tests. Methods: Nationally representative data from the 2022 Health Information National Trends Survey (HINTS 6) were used to assess awareness and use of ancestry, personal trait, specific disease, and carrier testing by sociodemographic characteristics, examine reasons for undergoing tests, and methods of accessing them. Results: Overall, 81.4% of respondents were aware and 40.0% had undergone testing. Only 10% of tests were ordered by genetic counselors, 80% of carrier and 65% of specific disease tests were ordered by other healthcare providers. Understanding family history was the most common reason for undergoing ancestry (72.2%) or personal trait tests (64.9%) whereas reasons such as doctor's recommendation (53%-59%), learning more about disease risk (18%-50%), and carrier testing (76%) were common for undergoing disease risk tests and carrier tests. In contrast to ancestry, personal trait, and carrier testing, there were no racial, ethnic, income, or rural/urban difference in use of specific disease risk testing. Discussion: Diffusion of genetic tests into US society, although incremental, has made sizable increases in awareness, equitable use of specific disease tests but worsening socioeconomic inequality in DTC genetic test use. The study provides update on the state of genetic testing in the US and identifies groups that may need help accessing clinical genomic information and services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.